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Submitted Oct 2, 2012; accepted Jan 27, 2013.DISCUSSIONDr Fred Weaver (Los Angeles, Calif). Chang and his fellow
authors report a large EVAR experience over a 10-year period in
the Northern California Kaiser Permanente Hospital system.
During this period, 1736 EVARs were performed in the 17
hospitals of the Northern California Kaiser system. As the authors
point out, the strength of this report and analysis is that it
provides a real world experience from which to critically evaluate
the beneﬁt of EVAR in patients with abdominal aortic aneurysms.
The results they report are not dissimilar to what has been
previously reported from EVAR registries, single-institutionexperiences, and prospective randomized trials. Namely, they
report a perioperative mortality of 1.2%, a long-term reintervention
rate of 15%, a 3% late aneurysm-related mortality, and a discour-
aging 66% overall survival at 5 years. These results conﬁrm that,
at least during the last decade, EVAR technology has been safely
transferred from selected large academic and community hospitals
to multiple hospitals of varying sizes that comprise this integrated
health care system. One aspect of this report that demonstrates the
strength of working within an integrated hospital system with elec-
tronic records is the outstanding longitudinal graft surveillance rate
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332 Chang et al August 2013of 91.8%. I have four questions for the authors to begin discussion
of this ﬁne paper.
1. You report 16 type III endoleaks in your series, which is
almost 1% of the patients in this experience. Although this is
a small number, we have found type III endoleaks to be rare
if nonexistent in our own experience. Do you have any infor-
mation regarding the devices used, the experience of the oper-
ators who placed the devices, or other factors that could have
contributed to the type III endoleaks?
2. You report 22 conversions, 9 graft infections, and 22 late
ruptures. Do you have additional information on these
patients? Did the patients with late ruptures fall out of
surveillance, did they have identiﬁed endoleaks, or did the
ruptures occur without these factors? What about the graft
infections; do you think these infections were implant-related
or occurred by blood stream seeding remote from the time of
implantation?
3. Why in an integrated health care system, is the penetration of
statin use so low? You mention this in your manuscript, and in
fact, your sister Kaiser system in Southern California has re-
ported that statin use in patients with aortic aneurysms has
a positive effect on survival. Given the disappointing 66%
survival at 5 years and the potential beneﬁt of statins, does
your integrated health care system have a plan to improve
the penetration of statin use in the aortic aneurysm
population?
4. You mention in the manuscript that you do not have informa-
tion on device selection and to what extent the Instructions for
Use (IFU) was stretched to accommodate EVAR in certain
patients. Your ﬁnding that postprocedure endoleaks, speciﬁ-
cally type I and III, large aneurysm size, and urgent EVAR
contributed to late aneurysm-related mortality, suggests that
less than optimal patient selection by criteria of the IFU is
a possibility. I would like your thoughts as to how in your
particular hospital system patient selection and management
might be improved to minimize these factors that impacted
aneurysm-related mortality.
Dr Chang. Thank you, Dr Weaver, for your thoughtful
comments.
1. You report 16 type III endoleaks in your series, which is
almost 1% of the patients in this experience. Although this is
a small number, we have found type III endoleaks to be rare
if nonexistent in our own experience. Do you have any infor-
mation regarding the devices used, the experience of the oper-
ators who placed the devices, or other factors that could have
contributed to the type III endoleaks?
Dr Chang.We were surprised to note the number of type III
leaks as well. We are further investigating these cases and hope to
report on them soon. They occurred with all devices, but we saw
a concerning number of late suture-hole leaks that led to several
cases of sac expansion and rupture.
2. You report 22 conversions, 9 graft infections, and 22 late
ruptures. Do you have additional information on these
patients? Did the patients with late ruptures fall out of surveil-
lance, did they have identiﬁed endoleaks, or did the ruptures
occur without these factors? What about the graft infections;do you think these infections were implant-related or occurred
by blood stream seeding remote from the time of implantation?
Dr Chang. These patients are also the subject of a study in
progress. We have detailed follow-up on these patients and are in
the process of obtaining anatomic information that might help
explain the need for open conversions. Due to the vigilance of
our registry nurses, no patient who elected to be followed was
lost to follow-up, so we’re looking at other adverse events as factors
leading to rupture. In terms of graft infections, we’ll report the
details, but the cohort is likely too small to make general state-
ments. Most of these graft infections were remote from the time
of implantation.
3. Why in an integrated health care system, is the penetration of
statin use so low? You mention this in your manuscript, and
in fact, your sister Kaiser system in Southern California has re-
ported that statin use in patients with aortic aneurysms has
a positive effect on survival. Given the disappointing 66%
survival at 5 years and the potential beneﬁt of statins, does
your integrated health care system have a plan to improve the
penetration of statin use in the aortic aneurysm population?
Dr Chang. Dr Weaver brings up an excellent point. Statin
use has been shown to be protective in patients with AAAs as
well as with cardiovascular disease in general. Although not rep-
resented in this historical cohort, Kaiser Permanente has made
statin use a cornerstone of our cardiovascular risk reduction
strategy. Since the adoption of this risk reduction program in
2004, we’ve had a large increase in statin use along with other
emphasized interventions, leading to dramatic reductions in
MI- and CV-related death. Our EVAR cohort likely reﬂected
an earlier group of patients who may not have enjoyed the pro-
longed beneﬁts of statin use. I would anticipate a future analysis
of contemporary patients to show a salutary effect of these aggres-
sive interventions.
4. You mention in the manuscript that you do not have informa-
tion on device selection and to what extent the IFU was
stretched to accommodate EVAR in certain patients. Your
ﬁnding that postprocedure endoleaks, speciﬁcally type I and
III, large aneurysm size and urgent EVAR contributed to
late aneurysm-related mortality, suggests that less than optimal
patient selection by criteria of the IFU is a possibility. I would
like your thoughts as to how in your particular hospital system
patient selection and management might be improved to
minimize these factors that impacted aneurysm-related
mortality.
Dr Chang. We agree that the absence of anatomic informa-
tion is a key limitation of this manuscript. Without a correlation
of anatomic descriptors and adherence to IFU, it is difﬁcult to
comment on practice patterns and to correlate device-related
events that might affect patient survival. I think the ﬁrst step to
improving patient selection is to understand our outcomes and
to ﬁll in the appropriate knowledge gaps. In this regard, we have
created a national EVAR registry within Kaiser Permanente
(including Southern California, Hawaii, the Paciﬁc Northwest,
Colorado, and the Mid-Atlantic regions). Our dataset will incorpo-
rate anatomic factors in addition to procedure outcomes to help us
answer these important questions.
